Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy

Cancer Journal from Scientific American

Volumn 5, Issue 3, 1999, Pages 152-158

  Hanks, Gerald E ^a   Hanlon, Alexandra L ^a   Pinover, Wayne H ^a   Horwitz, Eric M ^a   Schultheiss, Timothy E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Three dimensional conformal radiotherapy dose escalation

Indexed keywords

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033017133     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Johansson JE, Adami HO, Andersson SO et al. High 10-year survival rate in patients with early, untreated prostate cancer. JAMA 1992;267:2191-2196.
2. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-248.
3. Steinberg G, Bales G, Brendler C. An analysis of watchful waiting for clinically localized prostate cancer. 1998;159:1431-1436.
4. Baker L, Hanks G, Gershenson D et al. NCCN Prostate Cancer Practice Guidelines: the National Comprehensive Cancer Network. Oncology 1996;10 [11 suppl]:265-288.
5. Fleming C, Wasson JH, Albertsen PC et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2650-2658.
6. Hanks GE, Schultheiss TE, Hanlon AL et al. Dose escalation in the conformal treatment of prostate cancer: optimization is made possible by understanding the dose responses for control of cancer and late morbidity. Int J Radiat Oncol Biol Phys 1996;36:197.
7. Hanks GE, Schultheiss TE, Hanlon AL et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997;37:543-550.
8. Hanks GE, Hanlon AL, Schultheiss TE et al. Dose escalation with 3D conformal treatment: five-year outcomes, treatment optimization and future directions. Int J Radiat Oncol Biol Phys 1998;41: 501-510.
9. Pinover WH, Hanlon AL, Horwitz EM et al. Defining the appropriate dose for prostate cancer patients with PSA < 10 ng/ml. Int J Radiat Oncol Biol Phy 1998;42:142.
10. Hanks GE, Hanlon AL, Hudes G et al. Patterns of failure analysis of patients with high pretreatment PSA treated by radiation therapy: the need for improved systemic and loco-regional treatment. J Clin Oncol 1996;14:1093-1097.
11. Kuban DA, el-Mahdi AM, Schellhammer PF. Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology 1987;30:420-426.
12. Kuban D, el-Mahdi A, Schellhammer P. Potential benefit of improved local tumor control in patients with prostate carcinoma. Cancer 1995;75:2373-2382.
13. Fuks Z, Leibel SA, Wallner KE et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long term results in patients created with I-125 implantation. Int J Radiat Oncol Biol Phys 1991;21:537-547.
14. Beahrs OH, Henson DE, Hutter RV et al, eds. Prostate. In: Manual for Staging of Cancer. Philadelphia: JB Lippincott; 1992:177-182.
15. ICRU Report No. 50. International Commission on Radiation Units and Measurements: Prescribing, Recording, and Reporting Photon Beam Therapy. Washington, DC: International Commission on Radiation Units and Measurements, 1993.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:447-457.
17. Hanlon A, Fowble B, Hanks G. On the estimation of cause-specific failure probability and risk misinterpretation, bias, and incomplete analyses: Proceedings of the American Society for Therapeutic Radiology and Oncology 39th Annual Meeting. Int J Radiat Oncol Biol Phys 1997;39:217.
18. Kalbfleisch JD, Ross LP. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, 1980.
19. Pinover W, Hanlon A, Hanks G. bNED control: praying to a false god? Int J Radiat Oncol Biol Phys 1997;39:218.
20. Jean Owen. Personal communication, 1998.
21. Pollack A, Zagars G. External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? Urology 1998;51:258-264.